Back to Search
ANGEL LORENZO PORRAS MD
MD
Infectious Disease Physician
NPI: 1871156117IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
ME160980(FL)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
ME160980(FL)
Education
FLORIDA INTERNATIONAL UNIV, COLLEGE OF MEDICINE
Class of 2024
Research & Publications (20)
C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.
PMID 19324082·Cell Signal·2009
8-other
Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children.
PMID 18727804·Clin Microbiol Infect·2008
8-other
A role for p38alpha mitogen-activated protein kinase in embryonic cardiac differentiation.
PMID 18314011·FEBS Lett·2008
7-preclinical
Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1.
PMID 16844343·Cell Signal·2007
7-preclinical
Met acts on Mdm2 via mTOR to signal cell survival during development.
PMID 17329361·Development·2007
4-observational
p38alpha MAPK can positively or negatively regulate Rac-1 activity depending on the presence of serum.
PMID 17658519·FEBS Lett·2007
7-preclinical
Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?
PMID 17713627·Biomedica·2007
5-case
Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation.
PMID 17505786·Apoptosis·2007
8-other
Ovine serum and pituitary isoforms of luteinising hormone during the luteal phase.
PMID 16737642·Reprod Fertil Dev·2006
7-preclinical
Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.
PMID 17523760·Clin Drug Investig·2005
8-other
A comparison of nonlinear mixed-model analyses for a pediatric pharmacokinetic study.
PMID 15920891·J Biopharm Stat·2005
4-observational
Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.
PMID 15827104·J Clin Endocrinol Metab·2005
3-trial
P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli.
PMID 14617800·Mol Biol Cell·2004
7-preclinical
Pharmacokinetics of etoricoxib in patients with renal impairment.
PMID 14681341·J Clin Pharmacol·2004
8-other
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
PMID 15342613·J Clin Pharmacol·2004
3-trial
Correlation between DNA synthesis in the second, third and fourth generations of spermatogonia and the occurrence of apoptosis in both spermatogonia and spermatocytes.
PMID 14611640·Reproduction·2003
4-observational
Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.
PMID 17535062·Clin Drug Investig·2003
8-other
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
PMID 12638395·J Clin Pharmacol·2003
3-trial
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
PMID 14517196·J Clin Pharmacol·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 7800 SW 87TH AVE STE B260
MIAMI, FL 33173 - Phone
- (305) 595-4590
Quick Facts
- NPI
- 1871156117
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile